Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: VC Firm Invests in Seed-Stage Life Science Companies in North America and Europe Addressing Age-Related Diseases

3 Feb

A venture capital platform with a dedicated life sciences fund is focused on Seed-stage investments. The fund typically invests around $1M per company and does not have a strict preference between leading rounds or co-investing. The firm is open to opportunities across North America and Europe.  

Within life sciences, the fund focuses on therapeutics, medtech, digital health, and broader biotech ecosystem companies addressing age-related diseases. Areas of interest include cardiovascular disease, cancer, respiratory illnesses, dementia, Alzheimer’s disease, diabetes, and kidney disease.  

Within therapeutics, the fund emphasizes “repair and replace” approaches, including regenerative medicine, gene therapy, and immunotherapy. In medtech, the fund is interested in wearables, biosensors, and remote patient monitoring technologies. In digital health, areas of focus include AI-driven drug discovery and solutions that optimize clinical trial execution. Within the biotech ecosystem, the fund is drawn to bioprinting, biomaterials, and drug delivery platforms.  

From a company and management team perspective, the firm seeks businesses with a strong scientific foundation, compelling and differentiated innovation, and the ability to scale. Management teams are expected to demonstrate a balanced mix of scientific expertise, business development capabilities, administrative leadership, and marketing experience. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Newly Established Corporate Venture Initiative Strategically Invests in Life Sciences and AI-Powered Healthcare Technologies

3 Feb

The firm is a newly established corporate venture capital operating platform launched as part of a large global conglomerate’s corporate strategy focused on value creation and long-term growth. The firm represents the parent organization’s first company-wide corporate venture capital initiative and is designed to make flexible investments across a broad range of sectors, particularly those with large future markets and high growth potential where the parent organization can contribute differentiated value through global networks, industry and customer access, and technology and academic partnerships.  

Through the firm, the parent organization aims to accelerate collaboration with startups, identify business opportunities beyond existing core businesses, commercialize emerging technologies, support industrial application, and enable international expansion.  

The firm primarily focuses on early-stage companies, starting at Seed stage, but is able to invest across Seed through later-stage opportunities. The firm invests across a broad set of innovation-driven sectors, including AI, software, bio and healthcare, robotics, aerospace, next-generation computing, and other advanced technology domains. The investment strategy emphasizes areas where the firm can actively support commercialization, industrial deployment, and global scaling by leveraging the parent organization’s extensive industrial ecosystem.  

From a company and management team perspective, the firm partners with startups that are aligned with a broader transformation agenda and are capable of leveraging a global industrial platform to achieve scalable growth and international reach. The firm favors founding teams with deep technical expertise, strong commercialization potential, and the ability to engage effectively with industry, academic, and corporate networks. Investments are typically structured as equity participation, with active strategic support through customer access, supply-chain capabilities, and global operational resources to accelerate growth and value creation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , ,

Hot Investor Mandate: USA-Based VC Firm Actively Invests in Seed to Series A AI and Computational-Driven Techbio Companies

3 Feb

The firm is a U.S.-based venture capital platform providing smart capital to early-stage companies in medicine, biotech, and bioengineering. The firm focuses on opportunities at the intersection of biotechnology and computation or AI. The firm’s investment sweet spot is between Seed and Series A, with initial check sizes typically ranging from $250K–$300K and up to $500K, with the potential for follow-on investments. The firm is open to both leading and co-investing and does not have specific requirements regarding board or observer seats. The firm primarily focuses on companies based in the United States.  

The firm invests in techbio opportunities that combine biotechnology with computational or AI-driven approaches. The firm is less interested in digital health companies that do not have a biotech or wet-lab component and prioritizes highly innovative technologies with novel mechanisms rather than incremental improvements. Modalities of interest include gene therapy, cell therapy, mRNA-based therapies, and platform technologies. The firm is indication-agnostic. From a development-stage perspective, the firm is most interested in assets at the preclinical stage or entering early clinical development, supported by in vitro and/or animal model data.  

The firm does not have specific requirements regarding the composition of a company’s management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Multi-Stage Investment Firm Seeks Early and Growth-Stage Companies Across All Life Science and Healthcare Sectors

3 Feb

A multi-stage healthcare and life sciences investment platform is focused on addressing areas of significant unmet medical need by backing companies across all stages of development. The firm applies a data science–driven investment approach, prioritizing businesses that leverage biology and large-scale data to transform healthcare delivery and outcomes.  

The firm is broadly interested across the healthcare landscape, including medical technology, therapeutics, diagnostics, laboratory equipment, healthcare IT, and R&D services. Within medical technology, the firm seeks companies with at least an alpha-stage prototype supported by initial efficacy data. Within therapeutics, the firm primarily targets assets in Phase II clinical development and will consider Phase I programs only when supported by clear efficacy data.  

From a company and management team perspective, the firm looks for a strong and capable management team to be in place. The firm is open to investing in both privately held and publicly traded companies. For private investments, the firm generally seeks to take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Multi-Billion AUM VC Firm Invests Up to $20M in Innovative Biotech and Medtech Platforms and Products

27 Jan

A venture capital platform specialized in life sciences and medical technology manages multiple funds with total assets under management of approximately $1.5B. The firm has been operating since 2014 and is managed by a professional team with diverse and deep industry experience. To date, the firm has completed more than 90 investments in high-growth-potential companies. Typical allocation sizes for their RMB funds range from RMB 30M to RMB 150M, with the ability to invest up to RMB 200M. For the USD fund, typical investments range from $5-10M, with the ability to invest up to $20M. 

The firm is open to investing globally across the broader biomedical sector, including medtech and biotech or therapeutics. The firm focuses on technology-driven, innovative platforms and products that demonstrate clear differentiation and meaningful value creation for patients and the healthcare system overall. Within biotech and therapeutics, the firm prefers companies at the angel or venture stages, particularly those addressing significant unmet clinical needs. 

From a company perspective, the firm prefers opportunities that are technology-driven, commercially viable, and capable of solving real-world healthcare problems. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Corporate VC Arm of Global Pharma Strategically Invests in Pre-Clinical Therapeutics in Areas Including Oncology, CNS, Immunology

27 Jan

A corporate venture capital arm of a global pharmaceutical company with a long operating history and an international footprint is actively seeking new investments. The parent organization operates worldwide and has expanded its global reach through strategic acquisitions in recent years. As part of its broader open innovation strategy, the parent organization actively pursues in- and out-licensing, early-stage partnerships, and strategic investments. The firm is responsible for executing strategic investments that support future partnering opportunities and help build the parent organization’s therapeutic pipeline. 

The firm was established a few years ago and operates from the United States. The firm manages an evergreen fund and focuses on pre-clinical startups with differentiated platforms and first-in-class programs in human therapeutics. The firm participates in Seed and Series A financing rounds, typically investing up to USD $5M initially, with the ability to invest up to USD $10M per company through follow-on capital. The firm is open to engaging with companies globally and has built a portfolio of more than a dozen investments, primarily across Europe and the United States. 

The firm targets pre-clinical to pre-IND, in-human therapeutics companies. Key areas of interest include oncology, neurology, immunology, and specialty disease areas such as fibrosis, endocrine disorders, and rare genetic diseases. The firm is modality-agnostic and considers small molecules, antibodies, nucleic acid-based therapies, and gene therapies. The firm does not invest in medical devices or diagnostics. 

The firm does not lead financing rounds. When co-investing or participating in syndicated rounds, the firm requires a board observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Hot Investor Mandate: VC Firm With Multiple Life Science-Focused Funds Seeks Early-Stage Therapeutics and AI-Enabled Technologies 

27 Jan

A venture capital platform associated with a leading global life sciences services provider manages multiple funds and focuses on investing in early-stage life science companies. The firm’s investment sweet spot spans from Seed through Series B stages. Initial check sizes typically range from USD $2–10M, with the ability to provide follow-on capital. The firm is open to both leading and co-investing and considers board or observer seats on a case-by-case basis. Backed by a major contract research organization, the firm leverages deep expertise in biotech research and development to deliver value beyond capital. 

The firm invests in biotech therapeutics, including small molecules, biologics, and drug discovery programs. Key areas of interest include oncology, immunology and inflammation, central nervous system diseases, and metabolic diseases, covering a broad range of commonly pursued indications. The firm evaluates opportunities from the pre-IND stage through Phase I clinical trials. In addition, the firm focuses on innovative AI-enabled healthcare opportunities with strong technological differentiation, including AI-integrated medical devices such as surgical robotics, brain–computer interfaces, and smart imaging systems, as well as AI-driven diagnostics, drug discovery acceleration platforms, and intelligent healthcare solutions designed to improve clinical efficiency and data-driven decision-making. 

The firm does not impose specific requirements regarding the composition of a company’s management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

← Older Entries